The Wellcome Trust Sanger Institute Purchases Production-Scale SNP Genotyping Solution From Illumina.
Illumina Inc. announced an agreement with the Wellcome Trust Sanger Institute for the purchase of Illumina's SNP genotyping solution. Illumina's solution will constitute an integral component of the Institute's extensive resources devoted to understanding the functional implications of SNP-based sequence variation in the human genome and other model organisms.
